Bion-1301 phase 3
WebNov 4, 2024 · Data was presented from Cohort 1 in Part 3 of the ongoing phase 1/2 multi-center trial (see www.clinicaltrials.gov, identifier NCT03945318) evaluating the safety, … WebAug 23, 2024 · The interim results from phase I (NCT03945318) and phase II (NCT04684745) studies were presented by Barratt et al. recently and preliminary efficacy of BION-1301 was observed in patients with IgAN (Barratt et al., 2024a). The results revealed that BION-1301 was well-tolerated in patients with IgAN who received a 450 mg dose …
Bion-1301 phase 3
Did you know?
WebJun 6, 2024 · The Phase 1 trial described here will characterize the safety, pharmacokinetic (PK), and pharmacodynamic (PD) profiles of BION-1301 in healthy volunteers (HV) and patients with IgAN. ... Parts 1 and 2 assess BION-1301 in HV, and Part 3 will assess BION-1301 in patients with IgAN. Parts 1 and 2 are double-blind, randomized, placebo … WebNov 4, 2024 · Chinook’s lead program is atrasentan, a phase 3 endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. BION-1301, an anti-APRIL monoclonal antibody, is being evaluated in a phase 1/2 trial for IgA nephropathy.
WebDec 8, 2024 · A single-dose non-human primate study administering intravenous BION-1301 at 0.3, 3 and 30 mg/kg dose levels, yielded PK parameters typical for IgG4 class antibodies and absence of tolerability issues. ... Following identification of a recommended Phase 2 dose, an expanded cohort will investigate clinical activity of single-agent BION-1301. The ... WebNov 4, 2024 · Updated data from Cohort 1 and initial data from Cohort 2 were presented from Part 3 of the ongoing phase 1/2 multi-center trial (see www.clinicaltrials.gov, identifier NCT03945318) evaluating the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and clinical responses of open-label BION-1301 treatment in …
WebNov 4, 2024 · Updated data from Cohort 1 and initial data from Cohort 2 were presented from Part 3 of the ongoing phase 1/2 multi-center trial (see www.clinicaltrials.gov, … WebMay 3, 2024 · Parts 1 and 2 of the Phase 1/2 study (NCT03945318) assessing single and multiple ascending doses of BION-1301 in HV are complete. Part 3 is an ongoing, open-label, multicohort design in patients with IgAN treated with BION-1301 for up to 1 year.
WebApr 13, 2024 · Chinook’s lead program is atrasentan, a phase 3 endothelin receptor antagonist for the treatment of IgA nephropathy and proteinuric glomerular diseases. BION-1301, an anti-APRIL monoclonal antibody, is being evaluated in a phase 1/2 trial for IgA nephropathy. CHK-336, an oral small molecule LDHA inhibitor for the treatment of …
WebPart 3 of Chinook's phase 1b study of BION-1301 is currently enrolling IgAN patients in an open-label setting, and Chinook expects to present a small subset of interim patient data in an oral presentation at the 58 th ERA-EDTA Congress in June, as well as additional patient data at the ASN Kidney Week 2024 in November. • how to scratch your backWeb1 day ago · SEATTLE, April 13, 2024 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development... how to scratch through text in excelWebApr 13, 2024 · Chinook Therapeutics, Inc. SEATTLE, April 13, 2024 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and ... how to scratch the back of your throatWebNov 4, 2024 · Chinook will host a live conference call and webcast today at 4:30 pm EDT to discuss the data from Cohort 1 of Part 3 of Chinook’s ongoing phase 1/2 study of BION-1301 in patients with IgAN as ... north park lincoln hertzhow to scratch with keyboard on virtual djWebApr 11, 2024 · Certain of the statements made in this press release are forward looking, including those relating to Chinook’s business, future operations, advancement of its product candidates and product ... how to scratch the line in excelWeb1 day ago · (EDGAR Online via COMTEX) -- false 0001435049 0001435049 2024-04-10 2024-04-10 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM... north park library